News / Taiwan / economic_daily
瑞基 (4171) Reports 8.58% Revenue Growth as SATLite System Expands Internationally
Health Technology · Biotechnology · economic_daily · 2026-09-11
4171
瑞基 (4171) posted an 8.58% year-to-date revenue increase, driven by strong demand for animal health testing and the successful overseas deployment of its SATLite NGS system.
What Happened
Financial Performance: 瑞基 reported an August consolidated revenue of NT$18.18 million, marking a 6.19% year-on-year increase and the third consecutive month of growth. The cumulative revenue for the first eight months of the year reached NT$153 million, up 8.58% compared to the same period last year.
Growth Drivers: The company's growth is primarily fueled by robust demand for aquatic pathogen testing in Southeast Asia and new contract wins in the Middle East and Africa. In the livestock sector, key markets including Saudi Arabia, Taiwan, Mexico, and the Philippines have contributed significantly to the order volume.
Technological Expansion: The company's SATLite next-generation sequencing (NGS) automated library preparation system has transitioned from the negotiation phase to actual deployment. The first two units were successfully installed in Malaysia in August, with the University Putra Malaysia (UPM) completing external testing for future academic publication.
Strategic Outlook: Looking ahead to Q4, 瑞基 plans to deepen the market penetration of its PCR on-site testing products. The company will participate in several international exhibitions in Indonesia, the U.S., and Saudi Arabia to further expand its footprint in the global veterinary and livestock testing sectors.